Remove Clinical Research Remove Clinical Supply Remove Clinical Trials
article thumbnail

[Webinar] How biotech companies can improve clinical supply planning and distrib…

The Pharma Data

Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.

article thumbnail

How to Optimize Drug Development by Combining FSO and FSP Models

PPD

Approaches to outsourcing clinical trials have changed significantly in recent years. It’s important to understand the differences between FSO and FSP solution models for outsourcing clinical trials and how best to combine approaches for optimization.

article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

Clinical Supply Manufacturing Integration with our manufacturing team, ensuring flexibility and adaptability to meet the evolving needs of your studies throughout your drug development program or study. Image GettyImages-897885148_pharmacy.jpg Tags Clinical Trials We can manufacture almost every dosage form on the market.

article thumbnail

PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer

The Pharma Data

In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases.

FDA 52
article thumbnail

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials, with Molecular Partners as sponsor of these trials.